The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years

British Journal of Urology

Volumn 80, Issue 6, 1997, Pages 875-879

  Kaplan, S A ^a   Te, A E ^a   Ikeguchi, E ^a   Santarosa, R P ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Anti hypertensive; Benign prostatic hyperplasia; Doxazosin; Terazosin

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; DOXAZOSIN; TERAZOSIN;

AGED; ARTICLE; ASTHENIA; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; HEADACHE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RHINITIS; URINE FLOW RATE; VERTIGO;

EID: 0031396533     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.00471.x     Document Type: Article

References (23)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9
2. McConnell JD, Barry MJ, Bruskewitz RC et al. Benign Prostatic Hyperplasia: Diagnosis and Treatment. Quick Reference Guide for Clinicians. AHCPR Publication No. 94-0583. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services. February 1994
3. Tsang KK, Garraway WM. Prostatism and the burden of benign prostatic hyperplasia on elderly men. Age Ageing 1994; 23: 360-4
4. Department of Veterans Affairs cooperative study of transurethral resection for benign prostatic hyperplasia. A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. J Urol 1993; 150: 1696-700
5. Mebust WK, Holtgrewe HL, Cockett ATK. Transurethral prostatectomy: immediate and post-operative complications. J Urol 1989; 141: 243-7
6. Wyatt MG, Stower MJ, Smith PJB, Roberts JBM. Prostatectomy in the over 80-year-old. Br J Urol 1989; 64: 417-9
7. Kirby RS. α-Blockers in BPH: Clinical aspects. In Cockett ATK, Khoury S, Aso Y et al. eds, Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia (BPH). Jersey: Scientific Communication International Ltd, 1996: 549-554
8. Vincent J, Meredith PA, Elliott HL, Reid JL. The pharmacokinetics of doxazosin in elderly normotensives. Br J Clin Pharmacol 1986; 21: 521-4
9. Sennello LT, Sonders RC, Glassman HN, Jordan DC, Luther RR. Effect of age on the pharmacokinetics of orally and intravenously administered terazosin. Clin Ther 1988; 10: 600
10. Kaplan SA. Doxazosin in the older male: efficacy in treating BPH. Eur Urol 1996; 29 (suppl 1): 17-23
11. Jardin A, Kirby R, Christensen MM, Janknegt R. Gillenwater J, Fawzy A. Doxazosin is equally well tolerated by older and younger normotensive men. J Urol 1995; 153: 273A, 179
12. Wilde MI, Fitton A, Sorkin EM. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in benign prostatic hyperplasia. Drugs Aging 1993; 3: 258-77
13. Khoury AF, Kaplan NM. Alpha-blocker therapy of hypertension: an unfulfilled promise. JAMA 1991; 266: 394-8
14. Lepor H. Nonoperative management of benign prostatic hyperplasia. Current pharmacological treatment. J Urol 1989; 141: 1283-9
15. Kaplan SA, Santarosa RP, Te AE. The incidence of hypertension in a population of men with benign prostatic hyperplasia: analysis based on the AUA symptom score and race. Eur Urol 1996; 30 (suppl 2): 99, 332
16. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol 1995; 29: 7-12
17. Lenz ML, Pool, JL Laddu, AR Varghese A, Johnston W, Taylor AA. Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions. Am J Hypertens 1995; 8: 133-45
18. Lowe CL. Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis. Urology 1994; 44: 46-51
19. Lowe F, Tuttle J, Marks S, Steidle C, Jacobs T, Padley RJ, for the HYCAT Investigator Group. Blood pressure effects of men with prostatism concurrently treated with anti-hypertensives and terazosin. J Urol 1995; 153: 272A, 176
20. Kaplan SA, Meade-D'Alisera P, Quinones S, Soldo KA. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia. Urology 1995; 44: 512-7
21. Kirby RS, Chapple CR, Sethia K et al. Morning versus evening dosing with doxazosin in benign prostatic hyperplasia: efficacy and safety. Eur Urol 1997; In press
22. Lepor H, Knapp-Moloney G, Sunshine H. A dose titration study evaluating terazosin, a selective, once-a-day alpha-1 blocker for the treatment of symptomatic benign prostatic hyperplasia. J Urol 1990; 144: 1393-7
23. 1A-adrenoreceptor antagonist. Analysis of a multinational, multi-centre, open label study assessing the long term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996; 29: 145-54